Abstract 30P
Background
Breast cancer research has recently focussed on PIV as a promising predictive marker for response to Neo-Adjuvant Chemotherapy in Locally Advanced Breast Cancer. By analysing pre-treatment complete blood counts we seek to elucidate the potential of PIV as a prognostic indicator, shedding light on its potential implications on cancer care. With an emphasis on blood-based biomarkers, this study aims to evaluate the role of PIV as a predictor of response to Neo-Adjuvant Chemotherapy in Locally Advanced Breast Cancer.
Methods
A prospective observational study was conducted in a tertiary care centre over one year wherein 105 patients with LABC were evaluated. A pre-treatment complete blood count was done 2 weeks prior to the start of chemotherapy. The PIV score was calculated by multiplying the neutrophil, platelet and monocyte counts (103/mL) and dividing the result by the lymphocyte count (103/mL). After completion of NACT, the pathologic response was evaluated by microscopic examination of the resected specimens and assessing the RCB scoring (0 to 3) based on the extent of residual cancer burden.
Results
Patients ranged from 28 to 80 years (20 patients aged < 40 years old, 61 patients aged 40 - 60 years old, and 24 patients aged > 60 years old). The association between RCB scores and PIV obtained statistical significance with P value < 0.05. ROC curve revealed a cut-off value of 395.60 with 67.1% sensitivity and 66.7% specificity to predict complete pathological response.
Conclusions
The analysis of blood markers, individual RCB score categories and their association with establishment of a cut-off value of PIV is a useful tool in predicting treatment response and survival outcomes in breast cancer patients undergoing Neo-Adjuvant Chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kidwai Memorial Institute of Oncology.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.